Santen Pharmaceutical (4536.T) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

4536.T · Stock Price

JPY 1,618+156 (+10.64%)

Market Cap: $3.3B

Historical price data

Market Cap: $3.3BPipeline: 38 drugs (19 Phase 3)Founded: 1890Employees: 4,000-5,000HQ: Osaka, Japan

Sector Ranking#22 in Small Molecule Drugs

Overview

Santen's mission is to contribute to the well-being of patients, society, and employees by addressing ophthalmic diseases through specialized innovation. The company has achieved a leading global position in ophthalmology with a robust commercial portfolio and a deep R&D pipeline focused on glaucoma, retinal diseases, and ocular surface disorders. Its strategy is built on a vertically integrated, ophthalmology-focused model that enables deep expertise, operational efficiency, and targeted global expansion in both developed and emerging markets.

OphthalmologyEye Care

Technology Platform

Proprietary ocular drug delivery systems including advanced formulations for corneal penetration and sustained-release technologies such as biodegradable implants and novel delivery mechanisms designed to extend dosing intervals and improve bioavailability for ophthalmic applications.

Pipeline

38

38 drugs in pipeline19 in Phase 3

Drug	Indication	Stage
Eybelis ophthalmic solution 0.002%	Normal Tension Glaucoma	Approved
Aflibercept Injection [Eylea]	Diabetic Macular Edema	Approved
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmi...	Open Angle Glaucoma, Ocular Hypertension	Phase 3
DE-117B Eye Drops + Latanoprost	Open Angle Glaucoma	Phase 3
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate opht...	Dry Eye	Phase 3

FDA Approved Drugs

1

VERKAZIANDAJun 23, 2021

Opportunities

The global ophthalmology market is experiencing robust growth driven by an aging population and rising rates of diabetes and myopia.

Santen is poised to capture significant value through its late-stage pipeline of sustained-release implants and biosimilars, which address critical unmet needs in glaucoma and retinal diseases, and through expansion in high-growth emerging markets.

Risk Factors

Key risks include clinical or regulatory setbacks for pivotal Phase 3 programs (DE-126, DE-130), intense competition from larger pharmaceutical companies with greater resources, ongoing pricing pressure and generic erosion of mature products, and execution challenges in global commercial expansion.

Competitive Landscape

Santen competes with pure-play ophthalmology leaders like Alcon and Bausch + Lomb, as well as the ophthalmology divisions of major pharma such as Roche, Regeneron, and Novartis. Its differentiation lies in its exclusive focus, deep therapeutic expertise, and vertically integrated model, though it must contend with the significant scale and R&D budgets of its larger rivals.